Traditional coil embolization slows blood flow to enable hemostasis. Sufficient platelet activation and intact coagulation cascade are required for hemostasis. Past studies have found that thrombocytopenia and/or coagulopathy are factors associated with failure of embolization to stop bleeding. Glue embolization is thought to not be affected by such factors to stop bleeding. To evaluate the efficacy of glue embolization to other forms of embolization, we retrospectively reviewed all emergent embolizations performed for bleeding. We reviewed imaging and medical charts for all embolizations for bleeding performed by interventional radiology at a large academic institution for 4 years. Patient demographics, labs, indication, procedure time, embolization site, embolic agent(s) used, procedures and clinical course were reviewed. For statistical significance, Wilcoxon test is used to test continuous variables and Fisher’s exact for categorical variables. A total of 42 embolization procedures were performed on patients who had INR of at least 1.5 or higher and/or platelets 100 or less. Eight patients had embolizations performed using glue as one of the agents and 34 patients had embolizations using any agent or combination of agents exclusive of glue. In non-glue cases (34 cases), coils were used 82% of the time, followed by gel foam (32%), particles (6%) and plugs (6%). Gel foam was almost always concurrently used with coils (72% of the time); only 3 cases used gel foam as the only agent. The most common target organ was bowel (48% of the cases), followed by solid organs (liver, spleen, kidney; 29%) and muscle (24%). No glue cases required repeat intervention versus 18 of the non-glue cases (43%, P < 0.05). The INR and platelet levels were not significantly different between the groups. The mean procedure time was lower for glue cases (95 minutes for glue versus 106 minutes for non-glue cases) but was not statistically different between the groups. Embolization with glue was found to be significantly more durable than with embolization with other agents in patients with thrombocytopenia and/or coagulopathy.